Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

BURNABY, British Columbia--(BUSINESS WIRE)--Oct 28, 2026--

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear, 2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy, 1 giving Canadians living with diabetes more time between sensor changes and fewer interruptions to daily routines.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028811764/en/

Importantly, broad reimbursement will be in place starting in November, helping make this advancement accessible. Dexcom G7 15 Day will be publicly reimbursed for many eligible people living with type 1 and type 2 diabetes across Canada next month. In addition, most Canadians with private health plans that currently provide CGM coverage will soon have access to the latest Dexcom CGM technology.

“For people living with diabetes, staying aware of their glucose is part of everyday life. Our goal is to make that experience simple, seamless and intuitive,” said André Côté, Vice President and General Manager, Dexcom Canada. “With Dexcom G7 15 Day, we’re delivering the longest-lasting 1 sensor on the market that does not compromise on accuracy and performance. We are also focusing on launching with significant public and private reimbursement already in place, helping more Canadians benefit from this technology right away.”

Designed to help people spend less time thinking about their CGM and more time living their lives, Dexcom G7 15 Day is the longest lasting 1 and most accurate 1 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry leading 15.5 days. 1,2 With an overall MARD of 8.0%, 3 the system builds on the performance of Dexcom CGM which is clinically proven to lower A1C and increase time in range. 4-8

Dexcom G7 15 Day sets a new standard in CGM technology that’s easy to use, painless to insert* and requires fewer sensor changes per month.

New with Dexcom G7 15 Day

Dexcom G7 features included with Dexcom G7 15 Day

“Living with type 2 diabetes means there is always something to think about, whether it’s checking my glucose levels or making decisions about my health,” said Malcolm Kelly, Dexcom Warrior. “Having a CGM that lasts longer means one less thing to manage and fewer interruptions to my routine. Those small changes can make a big difference when you’re living with diabetes.”

Dexcom is working closely with its automated insulin delivery partners and looks forward to extending the launch to their customers shortly as they finalize integration.

To learn more about Dexcom G7 15 Day, visit Dexcom.com/dexcom-g7-15-day.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in continuous glucose monitoring for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

Category: IR

* 96% of patients reported mild/no pain. † The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. ‡ Smart devices sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. § An internet connection is required for users to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient’s glucose data if the patient elects to share it with them through Dexcom Clarity. || Separate Dexcom Follow app and internet connection required. Users should always confirm readings on the Dexcom G7 app or receiver before making treatment decisions. 1 Dexcom, Data on File, 2026. 2 Dexcom G7 15 Day User Guide. 3 Garg SK, et al. Diabetes Technol Ther. 2025;27(6):413-502. 4 Beck RW, et al . JAMA. 2017;317(4):371-378. 5 Beck RW, et al . Ann Intern Med. 2017;167(6):365-374. 6 Martens T, et al. JAMA. 2021;325(22):2262-2272. 7 Oser TK, et al. N Engl J Med. 2026. doi: 10.1056/NEJMoa2608571. Epub ahead of print. 8 Welsh JB, et al . J Diabetes Sci Technol. 2024;18(1):143-147. 9 Polonsky WH, Fortmann AL. Diabetes Technol Ther. 2021;23(3):195-202.

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy, giving Canadians living with diabetes more time between sensor changes and fewer interruptions to daily routines.

The Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes.

ST. PETERSBURG, Fla. (AP) — Drew Rasmussen will start for Tampa Bay on three days' rest in Game 5 of the World Series against the Milwaukee Brewers on Wednesday night, trying to stave off elimination for the Rays.

A 31-year-old right-hander, Rasmussen threw 89 pitches over 3 2/3 innings in Game 2 on Saturday, getting no decision as Milwaukee rallied for a 5-4 victory and a 2-0 Series lead.

“Called Ras right after he’d left the ballpark, and he was 100% on board wanting the ball,” Rays manager Kevin Cash said. “He held out from throwing a bullpen yesterday with this possibly in the back of his mind that he’s going to go out and prepare. I think Ras, knowing him, he’s pretty motivated to get back out there and give us what he can. He wasn’t satisfied with how maybe Game 2 went.”

Rasmussen has had three major elbow operations in his career, including Tommy John surgeries in 2016 and 2017 and an internal brace procedure in 2023. The two-time All-Star was 16-5 with a 2.67 ERA in the regular season, including 9-3 in 15 starts at home.

Milwaukee manager Pat Murphy didn't think short rest would impact the Rays' ace.

“Knowing Ras the way we know Ras and the type of warrior he is — he’s one of the best pitchers in the league,” Murphy said. “He pitches well here at home. I don’t think any of that affects anything.”

Rasmussen served as an opener for the Rays in 2024 and made short starts on two days' rest after relief appearances.

Jacob Misiorowski was set to start on four days' rest for the Brewers, who have a 3-1 lead in the best-of-seven series after wasting a 12th-inning lead in a 4-3 loss Tuesday.

Tampa Bay used seven pitchers Tuesday: starter Griffin Jax along with relievers Kevin Kelly, Game 1 starter Nick Martinez, Bryan Baker, Tyler Wells, Cam Booser and Ian Seymour.

Rays third baseman Junior Caminero was in the lineup, batting third, after leaving Tuesday night's game for a pinch runner in the 12th inning.

Caminero limped, favoring his left foot, after he reached leading off the 12th on an error. He went from first to third on Liam Hicks' single, then was replaced.

“He’s been dealing with some lower-extremity injuries, but there’s a lot of guys that are nicked up right now playing through a lot,” Cash said. "Know that Cammy will be ready to go today."

See AP’s full MLB coverage here

Tampa Bay Rays third baseman Junior Caminero takes batting practice prior to Game 4 of baseball's World Series, Tuesday, Oct. 27, 2026, in St. Petersburg, Fla., between the Milwaukee Brewers and the Tampa Bay Rays. (AP Photo/Chris O'Meara)

Tampa Bay Rays pitcher Drew Rasmussen throws during first inning of Game 2 of baseball's World Series, Saturday, Oct. 24, 2026, in Milwaukee, between the Milwaukee Brewers and the Tampa Bay Rays. (AP Photo/Kayla Wolf)